Want to see AU:RCE full AI Analyst Report?

Recce Pharmaceuticals Ltd. (RCE) Price & Analysis

22 Followers

RCE Stock Chart & Stats

AU$0.38

AU$0.02(4.17%)

At close: Jul 27 4:00 PM EDT

AU$0.38

AU$0.02(4.17%)

Day’s Range― - ―

52-Week RangeAU$0.31 - AU$0.73

Previous CloseN/A

Volume134.82K

Average Volume (3M)78.42K

Market Cap

AU$99.38M

Enterprise ValueAU$124.87

Total Cash (Recent Filing)AU$2.69M

Total Debt (Recent Filing)AU$10.44M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Mar 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding305,770,080

10 Day Avg. Volume76,072

30 Day Avg. Volume78,419

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)-7.00

Price to Sales (P/S)0.00

P/FCF Ratio-11.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)AU$8.85M

Bulls Say, Bears Say

Bulls Say

Anti-infective PipelineThe company is focused on synthetic anti-infective medicines addressing bacterial infections and drug resistance, a persistent healthcare need. A specialized pipeline in this area could support long-term relevance if clinical development converts into approved products and commercial adoption.

Unmet Medical NeedTargeting infected wounds and serious bacterial infections linked to antibiotic resistance gives the development program a clear clinical rationale. Products that address treatment gaps may have durable demand and differentiation potential if efficacy and safety are demonstrated.

Clinical Development BreadthHaving topical and intravenous formulations broadens the potential use cases across localized and serious infections. This gives the pipeline multiple avenues for development and future commercialization, reducing reliance on a single formulation or treatment setting.

Bears Say

Revenue CollapseRevenue falling to zero in the latest annual period indicates that the company has not yet established a dependable commercial revenue base. Negative gross profit further weakens near-term operating quality and leaves future progress heavily dependent on development outcomes.

Persistent UnprofitabilityDeeply negative EBIT, EBITDA and net income across the reported periods show that the business remains far from operating breakeven. Continued losses can consume capital needed for clinical development and make sustainable self-funded growth difficult over the coming quarters.

Funding And Balance-sheet RiskNegative equity combined with higher debt and ongoing cash burn limits financial flexibility. Because operating and free cash flow remain negative, the company is dependent on external funding, creating dilution or refinancing pressure while development spending continues.

Recce Pharmaceuticals Ltd. News

Recce Pharmaceuticals Reports Lapse of Conditional Options

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals has notified the market of the...

4h ago

Recce Pharmaceuticals faces shareholder push for governance changes and board shake-up

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has received a shareholder notice under...

2d ago

Recce Sets 2026 AGM Date as It Advances Synthetic Anti-Infective Pipeline

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals has scheduled its 2026...

13d ago

Recce Investors Reject Option Issues and Placement Ratification at General Meeting

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals reported the results of...

29d ago

Recce Pharmaceuticals Issues Investor Presentation with Extensive Legal Disclaimers

The latest announcement is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals has released a general...

29d ago

Recce Pharmaceuticals Files ASX Corporate Governance Statement and Appendix 4G

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals has lodged its corporate governance statement...

1M ago

Recce Pharmaceuticals Narrows Loss as Global Anti-Infective Programs Advance

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an update. Recce Pharmaceuticals reported a narrower net loss for...

1M ago

Recce wins Australian approval to expand pivotal Phase 3 diabetic foot trial

An update from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals has secured approval from...

1M ago

Recce Director Lifts Stake via Share Purchase Plan

The latest announcement is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals disclosed a change in...

2M ago

Recce Pharmaceuticals Issues 250,000 New Shares Under Corporations Act Exemption

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an announcement. Recce Pharmaceuticals has issued 250,000 fully paid ordinary...

2M ago

RCE FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest share price was AU$0.30 and its highest was AU$0.73 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is AU$99.38M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 01, 2027 which is in 151 days.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Recce Pharmaceuticals Ltd. released its earnings results on Aug 31, 2026. The company reported AU$0.006 earnings per share for the quarter.

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 305,770,080 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Recce Pharmaceuticals Ltd. reported an EPS of AU$0.006 in its last earnings report. Following the earnings report the stock price went up 2.18%.

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:RCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.31%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.